Company Performance - Y-mAbs Therapeutics, Inc. reported a quarterly loss of $0.12 per share, better than the Zacks Consensus Estimate of a loss of $0.22, and an improvement from a loss of $0.15 per share a year ago, representing an earnings surprise of 45.45% [1] - The company posted revenues of $20.9 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 6.92%, compared to year-ago revenues of $19.93 million [2] - Over the last four quarters, Y-mAbs has surpassed consensus EPS estimates just once and topped consensus revenue estimates only once [2] Stock Performance - Y-mAbs Therapeutics shares have declined approximately 48% since the beginning of the year, contrasting with the S&P 500's decline of only 0.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.26 on revenues of $20.05 million, and for the current fiscal year, it is -$1.02 on revenues of $82.79 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Y-mAbs belongs, is currently in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry performance can significantly impact stock performance [5][8]

Financial Performance - Adherex Technologies Inc. reported a quarterly loss of $0.04 per share, better than the Zacks Consensus Estimate of a loss of $0.12, representing an earnings surprise of 66.67% [1] - The company posted revenues of $8.75 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 9.32%, but down from $25.38 million year-over-year [2] - Over the last four quarters, the company has only surpassed consensus EPS estimates once [2] Market Performance - Adherex Technologies shares have declined approximately 0.8% since the beginning of the year, compared to a decline of 0.6% for the S&P 500 [3] - The company's current consensus EPS estimate for the upcoming quarter is -$0.10 on revenues of $9.44 million, and for the current fiscal year, it is $0.03 on revenues of $54.54 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Adherex Technologies belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the company's stock may outperform the market based on current estimates [5][6]

Company Performance - Everi Holdings reported quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.11 per share, and down from $0.05 per share a year ago, representing an earnings surprise of -63.64% [1] - The company posted revenues of $181.3 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.03%, but down from $189.35 million year-over-year [2] - Over the last four quarters, Everi Holdings has not surpassed consensus EPS estimates and has topped consensus revenue estimates only twice [2] Stock Outlook - Everi Holdings shares have increased by approximately 4.1% since the beginning of the year, contrasting with the S&P 500's decline of -3.8% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.09 on revenues of $184.85 million, and $0.24 on revenues of $743.07 million for the current fiscal year [7] Industry Context - The Business - Services industry, to which Everi Holdings belongs, is currently ranked in the top 18% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Everi Holdings' stock performance [5] - The estimate revisions trend for Everi Holdings is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6]

Core Viewpoint - Immunome, Inc. reported a quarterly loss of $0.52 per share, which was better than the Zacks Consensus Estimate of a loss of $0.66, indicating a positive earnings surprise of 21.21% [1] Financial Performance - The company posted revenues of $2.93 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 28.33%, compared to revenues of $1.03 million in the same quarter last year [2] - Over the last four quarters, Immunome has only surpassed consensus EPS estimates once [2] Stock Performance - Immunome shares have declined approximately 29.8% since the beginning of the year, while the S&P 500 has only declined by 3.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.66 on revenues of $2.28 million, and for the current fiscal year, it is -$2.69 on revenues of $9.13 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Immunome belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

HF FOODS GROUP INC. (HFFG) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -46.15%. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.11, delivering a surprise of 22.22%.Over the last four quarters, the com ...

FiscalNote Holdings, Inc. (NOTE) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -20%. A quarter ago, it was expected that this company would post a loss of $0.10 per share when it actually produced a loss of $0.10, delivering no surprise.Over the last four quarters, the company has surpassed ...

分组1 - Integral Ad Science (IAS) reported quarterly earnings of $0.05 per share, exceeding the Zacks Consensus Estimate of $0.03 per share, compared to a loss of $0.01 per share a year ago, representing an earnings surprise of 66.67% [1] - The company posted revenues of $134.07 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.40%, and compared to year-ago revenues of $114.53 million [2] - IAS has surpassed consensus EPS estimates three times over the last four quarters, indicating a positive trend in earnings performance [2] 分组2 - The stock has underperformed, losing about 26.1% since the beginning of the year, while the S&P 500 declined by only 3.8% [3] - The current consensus EPS estimate for the coming quarter is $0.06 on revenues of $143.42 million, and for the current fiscal year, it is $0.28 on revenues of $592 million [7] - The Advertising and Marketing industry, to which IAS belongs, is currently in the top 40% of Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]

Core Insights - Natural Gas Services (NGS) reported quarterly earnings of $0.38 per share, exceeding the Zacks Consensus Estimate of $0.27 per share, but down from $0.41 per share a year ago [1] - The company achieved a 40.74% earnings surprise and has surpassed consensus EPS estimates in all four of the last quarters [2] - NGS posted revenues of $41.38 million for the quarter, surpassing the Zacks Consensus Estimate by 1.53% and up from $36.91 million year-over-year [3] Financial Performance - The earnings surprise of 40.74% indicates strong performance relative to expectations [2] - Revenue growth of 12.6% year-over-year from $36.91 million to $41.38 million demonstrates positive sales momentum [3] - The company has consistently exceeded revenue estimates, achieving this in three of the last four quarters [3] Market Position and Outlook - NGS shares have declined approximately 23.7% year-to-date, contrasting with the S&P 500's decline of 3.8% [4] - The current Zacks Rank for NGS is 4 (Sell), indicating expectations of underperformance in the near future [7] - The consensus EPS estimate for the upcoming quarter is $0.28, with projected revenues of $41.51 million, and for the current fiscal year, the EPS estimate is $1.18 on revenues of $171.3 million [8] Industry Context - The Oil and Gas - Mechanical and Equipment industry, to which NGS belongs, is currently ranked in the bottom 8% of over 250 Zacks industries, suggesting a challenging environment [9] - The performance of NGS may be influenced by broader industry trends, as top-ranked industries tend to outperform lower-ranked ones significantly [9]

Core Insights - Getty Images Holdings, Inc. reported a quarterly loss of $0.14 per share, significantly missing the Zacks Consensus Estimate of $0.03, marking an earnings surprise of -566.67% [1] - The company generated revenues of $224.08 million for the quarter ended March 2025, which was 4.71% below the Zacks Consensus Estimate, but slightly above the year-ago revenues of $222.28 million [2] - The stock has underperformed the market, losing about 13% since the beginning of the year compared to the S&P 500's decline of -3.8% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.03 on revenues of $236.26 million, and for the current fiscal year, it is $0.10 on revenues of $948.07 million [7] - The estimate revisions trend for Getty Images is currently unfavorable, resulting in a Zacks Rank 5 (Strong Sell), indicating expected underperformance in the near future [6] Industry Context - The Internet - Software industry, to which Getty Images belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a relatively strong industry performance [8] - Another company in the same industry, Domo, is expected to report a quarterly loss of $0.20 per share, with revenues projected to decline by 2.8% year-over-year [9]

Core Viewpoint - Karyopharm Therapeutics reported a quarterly loss of $2.77 per share, significantly better than the Zacks Consensus Estimate of a loss of $4.21, marking an earnings surprise of 34.20% [1] Financial Performance - The company posted revenues of $30.02 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 16.18%, compared to $33.13 million in the same quarter last year [2] - Over the last four quarters, Karyopharm has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Karyopharm shares have declined approximately 40.7% since the beginning of the year, while the S&P 500 has decreased by 3.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$3.90 on revenues of $39.29 million, and for the current fiscal year, it is -$14.05 on revenues of $150.29 million [7] Industry Outlook - The Medical - Drugs industry, to which Karyopharm belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]